Showing results (161-170 of 439) with videos related to
Sort By:
Pageof 44
Expert Opinion on Drug Safety|May 31, 2018
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinibMassimo Breccia, Fabio Efficace, Alessandra Iurlo, et al.Leukemia Research|July 3, 2010
Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patientsMassimo Breccia, Vincenzo Federico, Roberto Latagliata, et al.Annals of Hematology|August 20, 2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experienceSara Pepe, Emilia Scalzulli, Gioia Colafigli, et al.Journal of Clinical Medicine|October 14, 2022
Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment DiscontinuationMaria Cristina Puzzolo, Massimo Breccia, Paola Mariglia, et al.European Journal of Haematology|February 9, 2024
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuationAlessandro Laganà, Mauro Passucci, Sara Pepe, et al.Current Oncology (Toronto, Ont.)|July 25, 2022
Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or IntoleranceMassimo Breccia, Francesca Palandri, Paola Guglielmelli, et al.Annals of Hematology|January 17, 2007
Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropeniaCorrado Girmenia, Eleonora Russo, Ida Carmosino, et al.Annals of Hematology|February 23, 2018
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatmentMassimo Breccia, Francesca Palandri, Luigiana Luciano, et al.Annals of Hematology|June 7, 2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practiceEmilia Scalzulli, Matteo Molica, Danilo Alunni Fegatelli, et al.Expert Opinion on Drug Safety|June 14, 2024
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safetyAlessandro Laganà, Emilia Scalzulli, Maria Laura Bisegna, et al.Pageof 44